Biotechnology - Biotechnology, Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 109 results

Stada Arz and mAbxience to negotiate over adalimumab biosimilar

21-11-2014

German drugmaker Stada Arzneimittel and the biotech specialist mAbxience have agreed to negotiate over…

AbbVieadalimumabAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyHumiraLicensingMabxienceSTADA Arzneimittel

Janssen and HemoShear identify vascular health benefits of RA drugs

Janssen and HemoShear identify vascular health benefits of RA drugs

11-11-2014

US biotech firm HemoShear and Janssen Research and Development plan to report data showing that a subset…

ActemraAnti-Arthritics/RheumaticsBiotechnologyCardio-vascularHemoShearJanssen Research and DevelopmentJohnson & JohnsonResearchRochesirukumabUSA

AstraZeneca to showcase inflammation/ autoimmunity pipeline at ACR

AstraZeneca to showcase inflammation/ autoimmunity pipeline at ACR

11-11-2014

Anglo-Swedish pharma major AstraZeneca, with its global biologics R&D subsidiary MedImmune, will present…

anifrolumabAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseaseslesinuradMavrilimumabMedImmuneResearchSifalimumabUSA

BioOutsource preparing for biosimilars boom

03-11-2014

Scotland, UK-based vaccine and microbiological testing company BioOutsource today announced a major initiative…

Anti-Arthritics/RheumaticsBioOutsourceBiosimilarsBiotechnologyResearchRespiratory and Pulmonary

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Auxilium's supplemental Biologics Application for Xiaflex approved by FDA

Auxilium's supplemental Biologics Application for Xiaflex approved by FDA

21-10-2014

Specialty biopharma company Auxilium Pharmaceuticals has received approval from the US Food And Drug…

Anti-Arthritics/RheumaticsAuxilium PharmaceuticalsBiotechnologyRegulationUSAXiaflex

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

09-10-2014

US biotech major Amgen says its Phase III study evaluating the efficacy and safety of its biosimilar…

AbbVieABP 501AmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyDermatologicalsHumiraResearchUSA

Biotherapies could save millions of euros when treating auto-immune diseases

Biotherapies could save millions of euros when treating auto-immune diseases

08-10-2014

Health care providers could save millions of euros if biotherapies were used in the treatment of Crohn’s…

Anti-Arthritics/RheumaticsBiotechnologyEuropeFinancialHealthcareResearchTheradiag

Amgen updates on Prolia in postmenopausal osteoporosis

Amgen updates on Prolia in postmenopausal osteoporosis

16-09-2014

USA-based Amgen has released results from a new exploratory analysis of the open-label extension study…

AmgenAnti-Arthritics/RheumaticsBiotechnologyProliaResearchWomen's Health

Premium-price biologicals and novel therapies will drive psoriatic arthritis market growth

10-09-2014

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in…

AbbVieAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyEli LillyEuropeHumiraJapanMarkets & MarketingNovartisOtezlaStelaraUSAXeljanz

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

03-09-2014

USA-based drug developer Alder BioPharmaceuticals says it has regained the worldwide rights to clazakizumab,…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbclazakizumabGlobalInflammatory diseasesLicensing

J&J affiliate Cilag GmbH International acquires Covagen

J&J affiliate Cilag GmbH International acquires Covagen

25-08-2014

Cilag GmbH International, an affiliate of US health care giant Johnson & Johnson’s Janssen companies,…

Anti-Arthritics/RheumaticsBiotechnologyCilag GmbH InternationalCovagenFynomAbInflammatory diseasesJanssenJohnson & JohnsonMergers & Acquisitions

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

21-08-2014

Surveyed managed care organizations (MCOs) anticipate that their costs of covering biologic treatments…

Anti-Arthritics/RheumaticsBiotechnologyFinancialHealthcareImmunologicals

Daiichi Sankyo initiates testing of etanercept biosimilar in Japan

Daiichi Sankyo initiates testing of etanercept biosimilar in Japan

20-08-2014

Japanese drug major Daiichi Sankyo says it has started the Phase III trial of CHS-0214, an investigational…

Active rheumatoid arthritisAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyCoherus BioSciencesDaiichi SankyoEnbreletanerceptJapanPharmacologyResearchRheumatoid arthritis

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

09-07-2014

Shares of US biotech firm Celgene fell 3.5% in premarket trade, but were up 1.2% $86.75 by mid-morning…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneOtezlaResearchUSA

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

18-06-2014

China-based biotech firm 3SBio has entered into an exclusive license with Selecta Biosciences for pegsiticase…

3SBioAnti-Arthritics/RheumaticsBiotechnologyLicensingpegsiticaseSelecta Biosciences

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

12-06-2014

USA-based privately-held Epirus Biopharmaceuticals, focused on the development and commercialization…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyBOW015EPIRUS BiopharmaceuticalsinfliximabRemicadeResearch

EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

12-06-2014

French drug major Sanofi and partner US biotech firm Regeneron Pharmaceuticals have presented positive…

Anti-Arthritics/RheumaticsBiotechnologyRegeneronResearchSanofisarilumab

EULAR: Sustained outcomes with UCB’s Cimzia in spondyloarthritis

EULAR: Sustained outcomes with UCB’s Cimzia in spondyloarthritis

12-06-2014

Belgium’s leading drugmaker UCB today presented new long-term data on Cimzia (certolizumab pegol) in…

Anti-Arthritics/RheumaticsBiotechnologyCimziaResearchUCB

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

12-06-2014

US drug major Bristol-Myers Squibb has released new data from a Phase IIIb RA trial showing that the…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbOrenciaResearch

Timing of AstraZeneca’s positive pipeline announcement “pertinent” in wake of takeover battle with Pfizer, say GlobalData analysts

21-05-2014

Anglo-Swedish drug major AstraZeneca may have more ammunition to deliver on promises made to investors…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyImmunologicalsMavrilimumabMedImmuneResearchSifalimumab

Janssen pulls EU application for IV Simponi

19-05-2014

Janssen Biologics, a European subsidiary of US health care giant Johnson & Johnson, says it has withdrawn…

Anti-Arthritics/RheumaticsBiotechnologyEuropeJanssenJohnson & JohnsonRegulationSimponi Injection

Celgene gains rights to Nogra product in potential $1 billion-plus deal

Celgene gains rights to Nogra product in potential $1 billion-plus deal

24-04-2014

US biotech firm Celgene has entered a global license agreement with privately-held Irish company Nogra…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneGED-0301LicensingNogra Pharma

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

1 to 25 of 109 results

Parexel

Parexel

Back to top